Key result
Soluble ACE2 shows potential as a diagnostic or prognostic biomarker for LV dysfunction.
Why the study?
BNP and NT-proBNP are commonly used in heart failure, but soluble ACE2 may have a potential role as an LV dysfunction diagnostic or prognostic biomarker.
Answers are grounded in this paper and cite their sources.
Soluble ACE2 may serve as a novel diagnostic and prognostic biomarker for left ventricular dysfunction, complementing established markers like BNP and NT-proBNP.
Left ventricular (LV) dysfunction is a part of the common pathophysiologic mechanism for the development of heart failure (HF). LV dysfunction can be classified into left ventricular systolic dysfunction (LVSD) and left ventricular diastolic dysfunction (LVDD). Currently, B-type Natriuretic Peptide (BNP) and N-Terminal Pro-BNP (NT-proBNP) are the most common marker used to determine HF. Both of them are used as diagnostic and prognostic marker. Angiotensin Converting Enzyme 2 (ACE2) was found as an ACE homolog, located in the cell membrane of the heart. ACE2 has a cardioprotective role in turning AngII to Ang1-7. ACE2 can be cleaved by A Disintegrin and Metalloproteinase 17 (ADAM17)/TNF-a converting enzyme (TACE) so that it can be detected in the plasma as soluble ACE2. Soluble ACE2 possessed a potential role as LV dysfunction diagnostic or prognostic biomarker. J MEDICINE 2021; 22: 127-131
No takes yet. Share an insight, caveat, or question.
Laksono et al. (2021) conducted a review in Left ventricular dysfunction and heart failure. Soluble Angiotensin Converting Enzyme 2 (ACE2) was evaluated. Soluble ACE2 possesses a potential role as a diagnostic or prognostic biomarker for left ventricular dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: